Valuation: Seelos Therapeutics, Inc.

Market Cap 101K 92.24K 84.99K 77.31K 145K 9.38M 152K 1.03M 411K 5.12M 380K 372K 16.08M P/E 2022
-0.98x
P/E 2023 -0.18x
Enterprise Value 11.33M 10.32M 9.51M 8.65M 16.23M 1.05B 17.06M 116M 46.01M 573M 42.52M 41.63M 1.8B EV / Sales 2022
-
EV / Sales 2023 11,278,456x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
698.88
5 years 0
Extreme 1.0E-6
8,121.61
10 years 0
Extreme 1.0E-6
28,761.63
Manager TitleAgeSince
Chief Executive Officer 66 31/12/2018
Investor Relations Contact - 31/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/02/24 Free

Chief Financial Officer

417 0.0043%
12/01/24 Free

Chief Financial Officer

24,537 0.2505%
12/01/24 Free

Chief Executive Officer

70,383 0.7186%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.24%-1.09%+33.67%+175.26% 40B
Weighted average by Cap. -1.48%-1.85%+32.16%+150.90%

Financials

2022 2023
Net sales - 2.2 2.01 1.85 1.68 3.16 204 3.32 22.5 8.94 111.42 8.27 8.09 349.69
Net income -73.53M -66.97M -61.71M -56.14M -105M -6.81B -111M -751M -299M -3.72B -276M -270M -11.67B -37.88M -34.5M -31.79M -28.92M -54.25M -3.51B -57.02M -387M -154M -1.92B -142M -139M -6.01B
Net Debt 4.59M 4.18M 3.85M 3.5M 6.57M 425M 6.91M 46.87M 18.63M 232M 17.22M 16.85M 728M 11.23M 10.23M 9.43M 8.57M 16.09M 1.04B 16.91M 115M 45.6M 568M 42.14M 41.25M 1.78B
Projected Income Statement - Annual - Seelos Therapeutics, Inc.
Logo Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.
Employees
8
Date Price Change Volume
20/11/26 US$0.000000 - 4

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Seelos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SEELQ Stock